Early experience with tixagevimab/cilgavimab pre-exposure prophylaxis in patients with immune-mediated inflammatory disease undergoing B cell depleting therapy and those with inborn errors of humoral immunity

• Cassandra Calabrese,
• Elizabeth Kirchner,
• Alexandra Villa-Forte,
• Rula A Hajj-Ali,
• Brandon P Moss,
• James P Fernandez

Affiliations

Cassandra Calabrese

Department of Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, Ohio, USA

Elizabeth Kirchner

Department of Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, Ohio, USA

Alexandra Villa-Forte

Department of Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, Ohio, USA

Rula A Hajj-Ali

Department of Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, Ohio, USA

Brandon P Moss

Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic, Cleveland, Ohio, USA

James P Fernandez

Department of Allergy and Clinical Immunology, Cleveland Clinic, Cleveland, Ohio, USA